Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pfizer Inc announces Bococizumab (RN316) significantly reduced LDL Cholesterol in statin-treated adults with high cholesterol in A Phase 2b Study1


Thursday, 27 Mar 2014 08:00am EDT 

Pfizer Inc:Bococizumab (RN316) significantly reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study (1).Phase 2b results of a 24 week, randomized, placebo-controlled, dose-ranging study of investigational bococizumab, proposed generic name for RN316.Statin treated patients with high cholesterol were randomized to various doses of either bococizumab twice or once monthly subcutaneous administration or placebo.Study met its primary endpoint across all doses, showing that bococizumab significantly reduced low density lipoprotein cholesterol (LDL-C) from baseline compared to placebo in adults with high cholesterol also taking statin therapy.Percentage of patients reporting adverse events or serious adverse events was similar across placebo- and bococizumab-treatment groups. 

Company Quote

58.15
-0.06 -0.10%
25 Jul 2014